Previous work in our laboratory has shown that the internal environment of rats has reduced growth\x=req-\ promoting activity during the second half of gestation and this condition is associated with resistance to the anabolic effects of GH. The placenta appears to be responsible for this condition but injections of estradiol plus progesterone into virgin females did not mimic it. Accordingly, it seemed worthwhile to test the effects of a placental lactogen (PL) for possible growth inhibitory effects. In the present study the effects of human (h)PL on skeletal growth in young female rats and on the growth of embryonic tissue transplants under their kidney capsules were investigated. Human (h) and bovine (b) GH, and ovine prolactin (oPRL) were also tested to determine whether the results obtained with hPL were specific. Twice daily subcutaneous injections of a high dose of hPL (10mg/day), but not of oPRL (5 mg/day) for 7 days inhibited both host tail growth and tibial epiphyseal plate width, and growth of whole 10-day embryo transplants. Injections of hGH at 1 mg/day for 8 days significantly increased host skeletal growth and growth of 12-day embryonic head transplants; at the same dose, neither bGH nor oPRL affected growth of the embryonic heads or of the host tibial epiphyseal plate width, but the bGH increased host tail growth. By contrast, the 1 mg/day dose of hPL significantly reduced the host's tibial epiphyseal plate width, tail growth, and transplant growth; lower doses of hPL (10 and 100 \g=m\g/day) were also inhibitory. Although all the hormone treatments increased total serum IGF-1 levels in the females, none of them had a significant effect when compared to saline injected control animals. Thus, the growth-inhibitory effects of hPL treatment appear to be specific to that hormone and they are not mediated by depression of serum IGF-1 levels. If these effects of hPL are mimicked by one or more of the rodent PLs, then the reduced growth-promoting activity and resistance to GH action that occurs in pregnant rats could be due to the rat PLs. These results indicate that in addition to having gl ucose\x=req-\ sparing effects in the mother, PLs could promote fetal growth by inhibiting growth of maternal tissues, which would thus spare other metabolites, such as amino acids and vitamins, for the conceptus.
Human placental lactogen (hPL) serves several impor¬ tant functions in pregnant women. Its diabetogenic action in the mother spares glucose for utilization by the conceptus (1) , and it may interact with other hormones to promote the breast growth that occurs during pregnancy (2) . Some evidence indicates that hPL may also function as a growth-promoting hormone, at least for the conceptus. Infusion of the hormone into pregnant rats between days 14 and 21 increased the weight of their fetuses on day 19 of gestation (3) , and it increased DNA synthesis in human fetal cells in culture (4) . In addition, hPL has weak GH-like effects in hypophysectomized rats (5, 6) and in hypopituitary and diabetic humans (7) . These latter effects led to the proposal that hPL should be named human chorionic somatomammotropin (hCS) by Grumbach and Kaplan (5) .
Although rodent PLs do not have significant GH-like activity (8) , the idea that hPL functions as a gestational growth-promoting hormone received support from studies with ovine (o) and bovine (b) PL, which have appreciable GH-like effects (9) (10) (11) . Other evidence indi¬ cates that the liver of fetal humans and sheep contains specific receptors for hPL and oPL, respectively (12, 13) . serum levels of IGF-1, and a substantial decline in the responsiveness of maternal tissues to the somatotrophic action of GH (17) . Other investigators have also reported that serum IGF-1 levels decline in pregnant rats (18) (19) (20) . However, during lactation, serum IGF-1 returned to about prepregnancy levels (17, 18) despite the persist¬ ence of reduced growth-supporting activity of the inter¬ nal milieu of the females (17) .
Cooke et al. (16) showed that the reduced growth- 
Embryo transplants
In the first experiment, whole 10-day embryos were transplanted as described by Liu et al. (23) . In two other studies, heads from 12-day embryos were transplanted because they were easier to handle than the 10-day embryos. Donor (27) , as appropriate.
Results Fig. 1 shows that after seven days of treatment, the oPRL injections (at 5 mg/day) had no effect on the growth of the whole embryo transplants or on the two growth indices in the hosts. However, the final wet weight of transplants in hPL-treated hosts (at 10 mg/day) was reduced by 35% compared to the control transplants.
Furthermore, the hPL-treated hosts had TEPWs and tail growth that were reduced by 20% (p<0.01) and 36% (p<0.05), respectively. (4) and it has some growth-promoting activity in rats (6, 30) and humans (7) . However, these positive effects with hPL were obtained in systems in which growth was retarded. The culture experiments measured prolifer¬ ation of cells grown in low serum conditions (4) and the in vivo studies involved hypophysectomized rats (6, 30) or either hypopituitary or diabetic humans (8 (10) and hepatocytes (31) .
In our previous studies on the growth of fetal and embryo transplants in pregnant rats, clear inhibition of growth was observed during the second half of gestation, while the fetuses in the uterus of these hosts grew rapidly (16, 17) . These results indicate that the placenta protects the conceptus from the anti-anabolic actions of PL (or other placental factors) in the maternal compart¬ ment. It is also possible that hPL has growth-promoting effects on the fetus in utero, even though we found it to be growth-inhibiting on fetal transplants in the extrauterine compartment.
In an earlier study, Josimovich (32) (33, 35, 36) and PL (37) (38) (39) . Of particular interest here is the hGH-variant (hGH-V) that differs in amino acid sequence from pituitary hGH at 13 residues (40) . Serum levels of hGH-V increase from mid-gestation to term (41) , following a pattern similar to that of hPL (42 (1, 8, 28) , and it is well established that insulin is necessary for normal growth both pre-and post-natally (46) . This effect would be important in the mother as it would reduce maternal use of substrates in addition to glucose that are needed for fetal anabolism, such as amino acids and vitamins.
